These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11054443)

  • 21. Risk-adapted approach for fever and neutropenia in paediatric cancer patients--a national multicentre study.
    Miedema KG; Tissing WJ; Abbink FC; Ball LM; Michiels EM; van Vliet MJ; de Vries WY; Kamps WA; Norbruis OF; Fiocco M; de Groot-Kruseman HA; van de Wetering MD; de Bont ES
    Eur J Cancer; 2016 Jan; 53():16-24. PubMed ID: 26700076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
    Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
    Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
    Cumpston A; Craig M; Hamadani M; Abraham J; Hobbs GR; Sarwari AR
    Transpl Infect Dis; 2013 Apr; 15(2):142-9. PubMed ID: 23279656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.
    Mathew S; Adel N; Rice RD; Panageas K; Duck ET; Comenzo RL; Kewalramani T; Nimer SD
    Bone Marrow Transplant; 2010 Oct; 45(10):1522-7. PubMed ID: 20062102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of an evidence-based order set to impact initial antibiotic time intervals in adult febrile neutropenia.
    Best JT; Frith K; Anderson F; Rapp CG; Rioux L; Ciccarello C
    Oncol Nurs Forum; 2011 Nov; 38(6):661-8. PubMed ID: 22037329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia.
    Bucaneve G; Menichetti F; Del Favero A
    Pharmacoeconomics; 1999 Jan; 15(1):85-95. PubMed ID: 10345160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.
    Dranitsaris G
    Pharmacoeconomics; 1999 Oct; 16(4):343-53. PubMed ID: 10623363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral versus intravenous antibiotics in treatment of paediatric febrile neutropenia.
    Vedi A; Cohn R
    J Paediatr Child Health; 2013 Mar; 49(3):170-8. PubMed ID: 22136103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?
    Karthaus M; Carratalà J; Jürgens H; Ganser A
    Chemotherapy; 1998; 44(6):427-35. PubMed ID: 9755304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefepime and amikacin as empirical therapy in patients with febrile neutropaenia: a single-centre phase II prospective survey.
    Mebis J; Vandeplassche S; Goossens H; Berneman ZN
    Acta Clin Belg; 2009; 64(1):35-41. PubMed ID: 19317239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
    Girmenia C; Russo E; Carmosino I; Breccia M; Dragoni F; Latagliata R; Mecarocci S; Morano SG; Stefanizzi C; Alimena G
    Ann Hematol; 2007 Apr; 86(4):263-70. PubMed ID: 17225113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
    Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
    J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.
    Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK
    Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
    Mitchell PL; Morland B; Stevens MC; Dick G; Easlea D; Meyer LC; Pinkerton CR
    J Clin Oncol; 1997 Mar; 15(3):1163-70. PubMed ID: 9060560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia.
    Bosi A; Laszlo D; Bacci S; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi-Ferrini P
    J Chemother; 1999 Aug; 11(4):287-92. PubMed ID: 10465131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.